Home » FDA Extends Homeopathic Draft Guidance Comment Period
FDA Extends Homeopathic Draft Guidance Comment Period
The FDA extended its comment period for draft guidance on homeopathic drug products for 60 days to May 21. The agency originally released the guidance on Dec. 20, 2017 with a 90-day comment period.
The draft guidance describes how the FDA intends to prioritize enforcement and regulatory action for drug products, including biological products, labeled as homeopathic and marketed in the United States without the required FDA approval.
The agency said the extension for more stakeholder comment would not cause a significant delay in the publication of the final guidance.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May